According to Tianyancha, BeiGene (Shanghai) Biotechnology Co., Ltd. was fined 400000 yuan by the Jing'an District Market Supervision Administration for promoting prescription drugs in violation of regulations.
According to the punishment reasons released by the Market Supervision Administration of Jing'an District, Shanghai, previously, the parties involved used Yilapao and promotional materials as carriers to publish advertisements for Pamipali capsules, claiming that "Baihuize (Pamipali) is the only PARP inhibitor approved for the treatment of 3L gBRCAm platinum sensitive and platinum resistant recurrent ovarian cancer". After investigation, Pamipali Capsules (Baihuize) are prescription drugs and can only be advertised in professional medical newspapers. The target audience for promotion must be professionals with medical knowledge. The above-mentioned behavior of the parties violates the relevant provisions of the Advertising Law and constitutes an illegal act of publishing prescription drug advertisements.